J&J seeks expanded approvals for paediatric HIV-1 therapy

2024-06-05
·
交易
Pharmaceutical Technology
上市批准临床研究
J&J seeks expanded approvals for paediatric HIV-1 therapy
Preview
来源: Pharmaceutical Technology
The fixed-dose combination of PREZCOBIX/REZOLSTA is a collaborative effort between Janssen R&D Ireland and Gilead. Credit: Dmytro Zinkevych/ Shutterstock.
Johnson & Johnson (J&J) has filed a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking expanded approval for the use of its HIV-1 therapy, PREZCOBIX  (darunavir/cobicistat), in children aged six years and above.
Recommended Buyer's Guides
J&J seeks expanded approvals for paediatric HIV-1 therapy
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
J&J seeks expanded approvals for paediatric HIV-1 therapy
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
Approval is being sought for PREZCOBIX use in paediatric patients weighing a minimum of 25kg.
In Europe, the company has submitted applications to the European Medicines Agency for the paediatric use of the medication, marketed as REZOLSTA.
Approval of the applications would enable PREZCOBIX/REZOLSTA to be administered to both adults and paediatric patients from the age of six years.
A new paediatric formulation has been developed, featuring a lower dose tablet (darunavir 675mg/cobicistat 150mg) making it easier for children to swallow.
See Also:The tiny pills that may send shockwaves across immunology
J&J seeks expanded approvals for paediatric HIV-1 therapy
Preview
来源: Pharmaceutical Technology
Roche’s PI3K inhibitor secures breakthrough status in breast cancer
J&J seeks expanded approvals for paediatric HIV-1 therapy
Preview
来源: Pharmaceutical Technology
The applications are supported by data from a clinical study, sponsored by Janssen Research & Development (R&D), which indicated that the new combination tablet is bioequivalent to the individual doses of darunavir and cobicistat.
A Phase II/III clinical trial by Gilead Sciences has established the efficacy, safety and tolerability of cobicistat-boosted darunavir in treating younger children with HIV-1.
PREZCOBIX/REZOLSTA combines darunavir, an HIV-1 protease inhibitorHIV-1 protease inhibitor, with cobicistat, a CYP3A inhibitor that enhances the pharmacokinetics of the therapy, allowing for once-a-day dosing.
The therapy is currently approved for use in adults and adolescents weighing a minimum of 40kg without resistance mutations to darunavir.
Darunavir is marketed by Janssen Products as PREZISTA in the US, and cobicistat, developed by Gilead Sciences, is sold as TYBOST.
The fixed-dose combination of PREZCOBIX/REZOLSTA is a collaborative effort between Janssen R&D Ireland and Gilead.
Johnson & Johnson infectious diseases and vaccines and global public health R&D global therapeutic area head Penny Heaton stated: “We are proud of this latest step in our years of work to ensure that some of the youngest people living with HIV have access to different treatment regimens that can work for them.
“If approved, this medicine could offer healthcare providers a new treatment option that ensures weight-appropriate dosing to better meet the needs of young people living with HIV.”
The latest development comes after Johnson & Johnson gained the global rights to Numab Therapeutics’ investigational first-in-class antibody, NM26 for atopic dermatitis.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。